According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “
Other research analysts have also issued research reports about the company. Raymond James initiated coverage on BRAINSWAY LTD/S in a research report on Monday, May 13th. They set an “outperform” rating and a $14.00 price target on the stock. Cantor Fitzgerald started coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They issued an “overweight” rating and a $17.00 price objective on the stock. LADENBURG THALM/SH SH started coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They issued a “buy” rating and a $19.00 price objective on the stock. Oppenheimer started coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They issued an “outperform” rating and a $17.00 price objective on the stock. Finally, CIBC started coverage on BRAINSWAY LTD/S in a report on Monday, May 13th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $15.80.
Shares of NASDAQ:BWAY traded up $0.25 during trading on Monday, hitting $9.25. 3,400 shares of the company’s stock traded hands, compared to its average volume of 13,214. BRAINSWAY LTD/S has a 52 week low of $8.00 and a 52 week high of $12.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.33 and a quick ratio of 1.33. The firm has a 50-day simple moving average of $10.03.
BRAINSWAY LTD/S (NASDAQ:BWAY) last released its quarterly earnings data on Wednesday, May 29th. The company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. The business had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.00 million. On average, research analysts expect that BRAINSWAY LTD/S will post -0.43 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter valued at $157,000. Noked Capital LTD bought a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter valued at $572,000. ARK Investment Management LLC bought a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter valued at $863,000. Finally, Delek Group Ltd. bought a new stake in shares of BRAINSWAY LTD/S during the 2nd quarter valued at $3,176,000. Hedge funds and other institutional investors own 3.64% of the company’s stock.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Story: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.